CN104582506B - 用于促进患有炎症性肠病(ibd)的患者的肌肉骨骼健康的营养组合物 - Google Patents
用于促进患有炎症性肠病(ibd)的患者的肌肉骨骼健康的营养组合物 Download PDFInfo
- Publication number
- CN104582506B CN104582506B CN201380040258.8A CN201380040258A CN104582506B CN 104582506 B CN104582506 B CN 104582506B CN 201380040258 A CN201380040258 A CN 201380040258A CN 104582506 B CN104582506 B CN 104582506B
- Authority
- CN
- China
- Prior art keywords
- acid
- alimentation composition
- vitamin
- alimentation
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 137
- 230000036541 health Effects 0.000 title claims abstract description 15
- 230000002757 inflammatory effect Effects 0.000 title claims description 41
- 230000001737 promoting effect Effects 0.000 title abstract description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 32
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 32
- 239000011712 vitamin K Substances 0.000 claims abstract description 32
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 32
- 229940046010 vitamin k Drugs 0.000 claims abstract description 32
- 235000016709 nutrition Nutrition 0.000 claims abstract description 22
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 15
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 15
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 15
- 239000011710 vitamin D Substances 0.000 claims abstract description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 15
- 229940046008 vitamin d Drugs 0.000 claims abstract description 15
- 235000019175 phylloquinone Nutrition 0.000 claims abstract description 14
- 239000011772 phylloquinone Substances 0.000 claims abstract description 14
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims abstract description 14
- 229960001898 phytomenadione Drugs 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005018 casein Substances 0.000 claims abstract description 12
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000021240 caseins Nutrition 0.000 claims abstract description 12
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims abstract description 9
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 7
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 208000004232 Enteritis Diseases 0.000 claims description 51
- 239000002253 acid Substances 0.000 claims description 38
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 210000003205 muscle Anatomy 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 230000037182 bone density Effects 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 229940024606 amino acid Drugs 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000035764 nutrition Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 10
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 9
- 239000006041 probiotic Substances 0.000 claims description 9
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 235000018291 probiotics Nutrition 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 7
- 150000001336 alkenes Chemical class 0.000 claims description 7
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 6
- 241000605909 Fusobacterium Species 0.000 claims description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 6
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 5
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 5
- 235000021290 n-3 DPA Nutrition 0.000 claims description 5
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 241000193798 Aerococcus Species 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000606125 Bacteroides Species 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241001478240 Coccus Species 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 4
- 241000192132 Leuconostoc Species 0.000 claims description 4
- 241000192041 Micrococcus Species 0.000 claims description 4
- 241000235395 Mucor Species 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 241000228143 Penicillium Species 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 4
- 241000186429 Propionibacterium Species 0.000 claims description 4
- 241000235070 Saccharomyces Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims description 4
- -1 carbon diene Chemical class 0.000 claims description 4
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 4
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Polymers 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 3
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- ZKCRKOCVERWCLP-DJWHJZFYSA-N Hiragonic acid Chemical compound C\C=C\CC\C=C\CC\C=C\CCCCC(O)=O ZKCRKOCVERWCLP-DJWHJZFYSA-N 0.000 claims description 3
- ZKCRKOCVERWCLP-UHFFFAOYSA-N Hiragonic acid Natural products CC=CCCC=CCCC=CCCCCC(O)=O ZKCRKOCVERWCLP-UHFFFAOYSA-N 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000235527 Rhizopus Species 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- GTBJRWFFEQJCHN-REOHCLBHSA-N (2s)-3-hydroxy-2-(hydroxyamino)propanoic acid Chemical compound OC[C@H](NO)C(O)=O GTBJRWFFEQJCHN-REOHCLBHSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 229920000310 Alpha glucan Polymers 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 241000235035 Debaryomyces Species 0.000 claims description 2
- 241001136487 Eurotium Species 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 241001468189 Melissococcus Species 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- 241000202223 Oenococcus Species 0.000 claims description 2
- 241000192001 Pediococcus Species 0.000 claims description 2
- 241000191992 Peptostreptococcus Species 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 241000202221 Weissella Species 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 claims 4
- 239000000835 fiber Substances 0.000 claims 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 2
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 claims 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 1
- 244000241257 Cucumis melo Species 0.000 claims 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 description 22
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000009326 ileitis Diseases 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000021196 dietary intervention Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000003650 acai Nutrition 0.000 description 2
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021324 borage oil Nutrition 0.000 description 2
- 230000021523 carboxylation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000015177 dried meat Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229910052567 struvite Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OUCUOMVLTQBZCY-BYPYZUCNSA-N (2s)-1-azaniumylpyrrolidine-2-carboxylate Chemical compound NN1CCC[C@H]1C(O)=O OUCUOMVLTQBZCY-BYPYZUCNSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- BIEZUWIUHAKFHZ-UHFFFAOYSA-N 2-hydroxy-2-methylpentanoic acid Chemical compound CCCC(C)(O)C(O)=O BIEZUWIUHAKFHZ-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- HQSBWLQFLLMPKC-BNFZFUHLSA-N 2E,4E-Dodecadienoic acid Chemical compound CCCCCCC\C=C\C=C\C(O)=O HQSBWLQFLLMPKC-BNFZFUHLSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001071905 Echium Species 0.000 description 1
- 240000002030 Ethulia conyzoides Species 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 102100027160 RuvB-like 1 Human genes 0.000 description 1
- 108050002982 RuvB-like helicase 1 Proteins 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098345 Triticum durum Species 0.000 description 1
- 235000007264 Triticum durum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- HQSBWLQFLLMPKC-UHFFFAOYSA-N dodecadienoic acid Natural products CCCCCCCC=CC=CC(O)=O HQSBWLQFLLMPKC-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000009491 menaquinone-4 Nutrition 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 150000005672 tetraenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1578—Calcium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1582—Chlorine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1586—Chromium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1588—Copper
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/159—Fluorine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1592—Iron
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1598—Iodine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/16—Potassium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1608—Molybdenum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/161—Magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1612—Manganese
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1614—Sodium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1618—Phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1626—Selenium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1642—Zinc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1872—Linoleic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1874—Linolenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1878—Medium-chain fatty acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1882—Polyunsaturated fatty acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54246—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/702—Vitamin A
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7042—Vitamin B1
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7046—Vitamin B3 niacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/705—Vitamin B5 pantothenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7056—Vitamin B8 Folic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/71—Vitamin D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/714—Vitamin K
- A23V2250/7142—Vitamin K1
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/714—Vitamin K
- A23V2250/7144—Vitamin K2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/72—Biotin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
公开了用于促进患有炎症性肠病患者的肌肉骨骼健康的营养组合物。营养组合物包含酪蛋白、维生素K1:K2的比率为3:1至1:3的维生素K且提供3.5‑20μg/100kcal营养组合物之间的维生素K、维生素D和α‑亚麻酸。还公开了包含营养组合物的药物制剂、营养制剂、管饲制剂、饮食补充剂、功能食品、饮料产品或其组合。还公开了用于改善肌肉骨骼健康的方法。
Description
发明领域
本公开涉及营养组合物、特别地是用于患有炎症性肠病的患者的营养组合物。本公开还涉及用于改善患者、特别地是患有炎症性肠病的患者的肌肉骨骼健康的方法。
发明背景
炎症性肠病是指牵涉胃肠道炎症的一组疾病。
局限性回肠炎是炎症性肠病的实例。局限性回肠炎可影响从口腔至肛门的整个胃肠道。
局限性回肠炎的确切病因尚不清楚。据信局限性回肠炎由与身体免疫系统相互作用的遗传、非遗传或环境因素(例如感染)的组合引起并且这影响胃肠道。
局限性回肠炎是其中身体免疫系统错误地袭击并破坏胃肠道的健康组织的慢性炎症性病症。局限性回肠炎的体征和症状牵涉发作和缓解的慢性复发期。
局限性回肠炎可导致胃肠道、肠外和全身并发症。胃肠道并发症可包括腹泻、腹痛、发烧和直肠出血。肠外并发症包括眼睛、骨骼、皮肤异常和血液异常的问题。此外,局限性回肠炎的肠外并发症导致造成骨质疏松症的骨密度减少或造成软骨病的骨软化增加。与局限性回肠炎有关的全身并发症包括儿童的生长延迟、由于食物摄入减少造成的重量减轻和进一步加剧重量减轻的碳水化合物或脂质的吸收不良。
没有针对局限性回肠炎的单一治疗。如果缓解局限性回肠炎是可能的,则可预防复发,并且症状通过药物治疗、改变生活方式、用营养组合物干预以及在一些情况下通过手术来控制。
对局限性回肠炎的治疗仅在症状活跃时是可能的。对局限性回肠炎的治疗通常牵涉首先治疗急性问题,然后保持缓解。
需要提供可校正患有局限性回肠炎患者的代谢变化并且预防并校正患有局限性回肠炎患者的局限性回肠炎相关改变的营养组合物。
需要能够监测患有局限性回肠炎的患者、能够在缓解期过程中预测局限性回肠炎在其发生之前的复发和缓解作用的可能性。用所谓的生物标记实现以这种方式监测患有局限性回肠炎的患者。生物标记允许可能进行早期营养干预以保持缓解状态。因此,需要鉴定可用作诊断工具的患有局限性回肠炎患者的生物标记。
已知营养组合物向患有炎症性肠病(例如局限性回肠炎)的患者提供单独营养组合物和/或补充营养组合物。营养组合物是炎症性肠病(例如局限性回肠炎)的首选疗法。营养组合物可能使炎症活动得以控制并且能使患者保持缓解状态。
由Nestlé制造的营养组合物-Modulen IBD是已知的。参见例如于2012年6月1日下载并浏览的产品信息单http://www.nestlenutrition.co.uk/healthcare/gb/products/Documents/Modu len%20IBD-nutritionpanel.pdf。Modulen IBD用于患有炎症性肠病(例如局限性回肠炎)的患者。已知Modulen IBD含有27μg/100g的量的维生素K。已知ModulenIBD含有4.9μg/100g的量的维生素D。已知Modulen IBD含有0.2g/100g的量的α-亚麻酸。Modulen IBD为基于酪蛋白的组合物。Modulen IBD中的酪蛋白提供抗炎症性细胞因子-转化生长因子-β2。已显示转化生长因子-β2在患有活跃炎症性肠病(例如局限性回肠炎)的儿童中诱导缓解。转化生长因子-β2因其控制炎症性活性而促进胃肠道的粘膜愈合。此外,转化生长因子-β2具有免疫调节性。
WO2011/031601公开了营养组合物以及制备和使用营养组合物的方法。营养组合物包括外源性维生素K2。营养组合物还可以包括选自磷、镁、锌、铁、铜、锰、钙、维生素D、骨桥蛋白及其组合的另外组分。
发明概述
需要提供促进患有炎症性肠病(例如局限性回肠炎)的患者的肌肉骨骼健康的营养组合物。
需要提供恢复患有炎症性肠病(例如局限性回肠炎)的患者的代谢特征的营养组合物。
患者可以为儿科或青少年患者。儿科患者为年龄为0至18岁、0至17岁或0至17岁的患者。0的年龄是指与出生是否为早产无关的出生时间。青少年患者为年龄为13至19、13至18、或13至17岁的患者。
第一方面,本公开涉及营养组合物。所述营养组合物包含酸性酪蛋白、维生素K1:K2的比率为3:1至1:3的维生素K且维生素K以17.5至100μg/100g营养组合物之间的量存在、以2.5至75μg/100g营养组合物的量存在的维生素D;和n6:n3脂肪酸的比率为5:1至1:5的n6/n3脂肪酸。
另一方面,本公开涉及包含营养组合物的药物制剂、营养制剂、管饲制剂、饮食补充剂、功能食品、饮料产品或其组合,所述营养组合物包含酸性酪蛋白、维生素K1:K2的比率为3:1至1:3的维生素K且维生素K以17.5至100μg/100g营养组合物之间的量存在、以2.5至75μg/100g营养组合物的量存在的维生素D;和n6:n3脂肪酸的比率为5:1至1:5的n6/n3脂肪酸。
另一方面,本公开涉及改善儿科患者的肌肉骨骼健康的方法。所述方法包括向需要其的儿科患者施用营养组合物,所述营养组合物包含酸性酪蛋白、维生素K1:K2的比率为3:1至1:3的维生素K且维生素K以17.5至100μg/100g营养组合物之间的量存在、以2.5至75μg/100g营养组合物的量存在的维生素D;和n6:n3脂肪酸的比率为5:1至1:5的n6/n3脂肪酸。
附图简述
图1示出当用根据本公开的营养组合物施用时年龄为6.6-17.7岁的患有局限性回肠炎的儿童的儿科局限性回肠炎活动指数(PCDAI)。
图2示出当向年龄为6.6-17.7岁的患有局限性回肠炎的儿童施用时本公开的营养组合物对骨密度和肌肉横截面积的影响。
详细描述
为了完全理解本公开及其优点,与附图结合参考下列详细描述。
应理解,本文公开的本发明的各个方面仅仅说明了制备并使用本公开的特定方法并且当考虑所附权利要求、详细描述和附图时不限制本公开的范围。
应理解,本领域技术人员根据本文公开的本公开的描述或实施例应明了本公开的一个方面的特征,并且那些特征可与本公开的其它方面/实施方案的特征组合。
如在本公开和所附权利要求中使用,除非上下文另外清楚指明,否则单数形式“一个/种”和“该”包括复数指示物。
本发明人已开发炎症性肠病(例如局限性回肠炎)的营养组合物。
术语“营养组合物”包括但不限于完全营养组合物、部分或不完全营养组合物,和疾病或疾患特异性营养组合物。完全营养组合物(即含有所有必要常量和微量营养素的那些)可用作患者的单一营养来源。患者由此类完全营养组合物可接受100%的其营养需求。部分或不完全营养组合物不含所有必要的常量和微量营养素并且不能用作患者的单一营养来源。部分或不完全营养组合物可用作营养补充剂。疾病或疾患特异性营养组合物为递送营养素或药物的组合物并且可以为完全或部分营养组合物。
已发现,营养组合物当在炎症性肠病(例如局限性回肠炎)活跃期使用时:可诱导缓解(如通过PCDAI评分和内窥镜评估所指示)可下调炎症性响应,促进肠粘膜愈合,可促进重量增加,可促进线性生长且改善营养状况以及改善肌肉骨骼变化。
PCDAI评分为本领域熟知的且PCDAI是指儿科局限性回肠炎活动指数。PCDAI为可靠的、经验证的多参数测量,其分类儿童和青少年中的疾病活性。发现本公开的营养组合物在治疗的前两周内显著地减少PCDAI–在8周内减少至最小值,如图1中描述。
营养组合物包含酸性酪蛋白、维生素K1:K2的比率为3:1至1:3的维生素K且维生素K以17.5至100μg/100g营养组合物之间的量存在、以2.5至75μg/100g营养组合物的量存在的维生素D;和n6:n3脂肪酸的比率为 5:1至1:5的n6/n3脂肪酸。
酸性酪蛋白通过对乳酸化直至达到酪蛋白的等电点(pH 4.7)而生成。随后,所谓的酸性酪蛋白沉淀。此方法在本领域是充分确立的(参见US4397926的背景部分)。通常,在变酸乳清的影响下、酪蛋白从准确脱脂的乳持续凝聚的过程中获得酸性酪蛋白。然而,其他生成方法是可用的。
酸性酪蛋白在天然存在的转化生长因子β-2(TGF-β2)中是高含量的。转化生长因子β-2(TGF-β2)是在肠粘膜愈合中起重要作用的抗炎症性细胞因子。
维生素K指示一组具有常见化学环结构(萘醌)的亲脂性、疏水性必需维生素。维生素K1是被称为叶绿醌或植物甲萘醌的单个化合物,且维生素K2是被称为甲基萘醌类或四烯甲萘醌(menatetrenones)的一系列维生素。
正如所述,已知炎症性肠病(例如局限性回肠炎)损害骨生长、骨质量,并且最终损害骨密度。患有炎症性肠病(例如局限性回肠炎)的患者中低骨量的发生率为约30-50%范围。维生素K通常在患有炎症性肠病(例如局限性回肠炎)的患者中缺乏并且继发的有限生物利用度可在骨量形成期间减少骨钙素羧化作用以及减少骨强度、骨矿化和骨微架构。因此,具有炎症性肠疾病(例如局限性回肠炎)的患者受益于更有效剂量的维生素K。低维生素K水平可导致骨再吸收的速率增加,而骨形成速率没有代偿行增加。
维生素K2在没有负面影响抗凝参数的情况下允许更有效形式的维生素K,而不是经由更高的维生素K1摄入来增加摄入水平。与维生素K1比较,维生素K2通过比维生素K1更长的半衰期而提供增强的吸收和更稳定的血清水平。维生素K2至肝外组织的吸收增强允许对改善患有炎症性肠病(例如局限性回肠炎)患者的肌肉骨骼健康产生更大的影响。
本申请人已令人惊讶地发现,施用作为营养组合物的部分的、维生素K1:K2的比率为3:1至1:3的维生素K且维生素K以17.5至100μg/100g营养组合物之间的量存在,会在儿童的正常生长和发育期间改善骨钙素羧化并改善骨健康指数。此外,维生素K补充还促进患有炎症性肠疾病(例 如局限性回肠炎)患者的骨生长和骨质量。营养组合物当在患有炎症性肠疾病(例如局限性回肠炎)的患者中施用时增加骨密度并且改善骨组织微架构,从而减少骨折风险的发生率。维生素K的作用在骨质量方面被直接观察到,从而这种形式的维生素K调控在涉及微架构形态学、矿化、密度、弹性和机械刚度的骨的有机基质中的蛋白质形成,如通过外周定量计算机断层摄影术(“pQCT”)或双能X射线吸收测量术(“DEXA”)所测量。
骨密度表示为骨量(表示为穿过骨的光子衰减程度,或骨矿物质含量(BMC))与胶片上的骨图像(即面积)之间的关系(表示为BMC/cm2)。此外,pQCT是在三维上评价外周骨的方法(测定体积)并且通常用于前臂或胫骨。辐射源(通常x射线)和传感器围绕所检查的骨旋转,然后在计算机屏幕上以三维图像重新构建。pQCT是评价骨几何形状的最佳技术,尽管灵敏度随着评价的位置而改变。与大多数其它技术不同,pQCT测量真实的骨密度(体积矿物质骨密度),因为它所归一化的骨矿物质含量不是由投影面积、而是由所检查的骨的体积推导的。pQCT还可用于计算SSI(骨抗扭转指数)。该指数考虑了骨几何形状和骨矿物质特征。参见Geometry and bone density,Radetti,G.,等人,Panminerva Med 2006;48:181-6。
DEXA基于x射线光谱测定法,其基本原理是基于由2种不同能量源发射的x射线的衰减程度。DEXA通常用于评价腰部或近侧股骨骨矿化。DEXA的准确度为4-10%,且变异系数为1-1.5%。
在一个优选实施方案中,维生素K以维生素K1:K2的比率为2:1至1:2的维生素K的量存在。
在一个优选实施方案中,维生素K以维生素K1:K2的比率为1:1的维生素K的量存在。
在一个优选实施方案中,维生素K以20至50μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素K以20至40μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素K以22至30μg/100g营养组合物的 量存在。
在一个优选实施方案中,维生素K以25至30μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素K以26至28μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素K以27/100g营养组合物的量存在。
维生素D是用于骨无机基质发育的重要营养素。维生素D以2.5至75μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素D以7.5至70μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素D以7.5至15μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素D以10至13μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素D以11至12μg/100g营养组合物的量存在。
在一个优选实施方案中,维生素D以11.6μg/100g营养组合物的量存在。
图2示出通过肠道喂食施用营养组合物12周可显著地改善年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的骨密度。
此外,由于n6/n3脂肪酸和/或其混合物的存在,营养组合物具有增强的用于粘膜愈合的抗炎症性活性。n6/n3脂肪酸以5:1至1:5的n6:n3脂肪酸的比率存在。因为营养组合物促进粘膜愈合,所以患有炎症性肠病(例如局限性回肠炎)的患者中营养素的吸收有所改善。
n3 ω-脂肪酸的实例为十六碳三烯酸(HTA)C16:3、α-亚麻酸(ALA)C18:3、十八碳四烯酸(SDA)C18:4、二十碳三烯酸(ETE)C20:3、二十碳四烯酸(ETA)C20:4、二十碳五烯酸(EPA)C20:5、二十一碳五烯酸(HPA)C21:5、二十二碳五烯酸(DPA)C22:5、二十二碳六烯酸(DHA)C22:6、二 十四碳五烯酸C24:5和二十四碳六烯酸C24:6。
在一个优选实施方案中,n3 ω-3-脂肪酸为二十碳五烯酸(EPA)C20:5和二十二碳六烯酸(DHA)C22:6。
n3 ω-3-脂肪酸可源自鱼油、藻油(algal oil)、鱿鱼油(squid oil)和植物油如蓝蓟油(echium oil)和亚麻籽油和/或其混合物。
n6、ω-6-脂肪酸的实例为亚麻酸(LA)C18:2、γ-亚麻酸(GLA)C18:3、二十碳二烯酸C20:2、二高-γ-亚麻酸(DGLA)C20:3、花生四烯酸(AA)C20:4、二十二碳二烯酸C22:2、肾上腺酸C22:4、二十二碳五烯酸C22:5、二十四碳四烯酸C24:4、二十四碳五烯酸C24:5和十八碳三烯酸C18:3。
n6 ω-6-脂肪酸可源自家禽、蛋、鳄梨、坚果、谷物、硬质小麦、全麦、蔬菜油、月见草油、琉璃苣油(borage oil)、黑醋粟(blackcurrant)籽油、亚麻/亚麻籽油、菜籽油、低芥酸菜子油、大麻油、大豆油、棉花籽油、葵花籽油、玉米油、红花油、南瓜籽、阿萨伊果(acaiberry)、腰果和螺旋藻属和/或其混合物。
在一个优选实施方案中,n3 ω-3-脂肪酸为α-亚麻酸(ALA)C18:3且n6 ω-6-脂肪酸为亚麻酸(LA)C18:2。
图2示出通过肠道喂食施用营养组合物12周可显著地改善年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的肌肉横截面积。
营养组合物还可以包括一种或多种氨基酸。氨基酸的非限制性实例包括丙氨酸、精氨酸、天冬酰胺、天冬氨酸、瓜氨酸、半胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、组氨酸、羟脯氨酸、羟基丝氨酸、羟酪氨酸、羟赖氨酸、异亮氨酸、亮氨酸、赖氨酸、蛋氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸、HICA(α-羟基异己酸)、HIVA(α-羟基异戊酸)、HIMVA(α-羟基甲基戊酸)或其组合。
在另一个实施方案中,营养组合物可以包含矿物质,如钠、钾、钙,磷、镁、氯化物、铁、锌、铜、锰、氟化物、铬、钼、硒、碘化物或其任何组合。
在另一个实施方案中,营养组合物还包含维生素,如维生素A、维生 素E、维生素C、维生素B1、维生素B2、泛酸、维生素B6、维生素B12、烟酸、叶酸、生物素和胆碱或其任何组合。
在另一个实施方案中,营养组合物还包括一种或多种益生元。如本文所使用,益生元为选择性发酵的成分,其允许在胃肠微菌群的组成和/或活性发生特定的改变,这些改变给宿主安康和健康带来益处。益生元的非限制性实例包括低聚果糖、菊粉、乳果糖、半乳低聚糖、阿拉伯树胶、大豆低聚糖(soyoligosaccharides)、低聚木糖(xylooligosaccharides)、低聚异麦芽糖(isomaltooligosaccharides)、低聚龙胆糖(gentiooligosaccharides)、低聚乳果糖(lactosucrose)、低聚葡萄糖、果胶低聚糖(pecticoligosaccharides)、瓜尔胶、部分水解的瓜尔胶、糖醇、α葡聚糖、β葡聚糖或其组合。
在另一个实施方案中,营养组合物还包括一种或多种益生菌。如益生菌优选为微生物(活的,包括半活的或弱化的、和/或非复制的)、代谢物、微生物细胞制备物或微生物细胞组分:当以足够的量施用时可以给宿主带来健康益处,更具体而言,可以通过改善其肠道微生物平衡而有益地影响宿主,从而对宿主的健康或安康产生作用。通常,据信这些益生菌抑制和/或影响致病菌在肠道中的生长和/或代谢。益生菌还可以激活宿主的免疫功能。益生菌的非限制性实例包括酵母属(Saccharomyces)、德巴利酵母属(Debaromyces)、念珠菌属(Candida)、毕赤酵母属(Pichia)、球拟酵母属(Torulopsis)、曲霉菌属(Aspergillus)、根霉菌属(Rhizopus)、毛霉菌属(Mucor)、青霉属(Penicillium)、双歧杆菌属(Bifidobacterium)、类杆菌属(Bacteroides)、梭菌属(Clostridium)、梭杆菌属(Fusobacterium)、蜜蜂球菌属(Melissococcus)、丙酸杆菌属(Propionibacterium)、链球菌属(Streptococcus)、肠球菌属(Enterococcus)、乳球菌属(Lactococcus)、葡萄球菌属(Staphylococcus)、消化链球菌属(Peptostrepococcus)、芽孢杆菌属(Bacillus)、片球菌属(Pediococcus)、微球菌属(Micrococcus)、明串珠菌属(Leuconostoc)、魏斯氏菌属(Weissella)、气球菌属(Aerococcus)、酒球菌属(Oenococcus)、乳杆菌属(Lactobacillus)或其组合。
另一个实施方案中,营养组合物还包含合生元(synbiotic)。合生元为含 有一种或多种益生元和一种或多种益生菌的补充剂。一种或多种益生元和一种或多种益生菌一起工作以改善肠道的微菌群。合生元包含上文提及的一种或多种益生元和一种或多种益生菌的任何组合。
在另一个实施方案中,营养组合物包含药学上可接受的载体和/或风味剂和/或着色剂。风味剂的使用向营养组合物提供使营养组合物对患有炎症性肠病(例如局限性回肠炎)的患者更可口的风味。
在一个优选实施方案中,营养组合物呈用液体重构的粉末形式。
营养组合物可以呈可施用形式,如药物制剂、营养制剂、管饲制剂、饮食补充剂、功能食品、饮料产品或其组合。
如本文所使用,“管饲”制剂优选为向患者胃肠道施用的完全或不完全营养产品,而不是通过口服施用,包括但不限于鼻胃管、口胃管、胃管、空肠造口术管(J-管)、经皮内镜胃造瘘术(PEG)、口(port)、如提供达到胃、空肠的胸壁口和其它适合的入口。
本公开的营养组合物在患有炎症性肠病(例如局限性回肠炎)的患者中是有利的,其希望避免用药物疗法的治疗以及避免与药物疗法相关的副作用。
本公开的营养组合物可作为药物疗法的补充剂用于患有炎症性肠病(例如局限性回肠炎)的患者中。
本公开的营养组合物在未能响应于药物治疗的患有炎症性肠病(例如局限性回肠炎)的患者中是有利的。
实施例
根据表1制造根据本公开的营养组合物。
“营养组合物的实例-成分/100g”这一列示出了当营养组合物呈粉末形式时,基于营养组合物成分/100g营养组合物的营养组合物的实例。
“每份公布值:20.4g营养组合物(粉末)/84ml水以形成100ml重构配方”这一列示出了当20.4g营养组合物实例用84ml水重构以形成100ml呈液体形式的营养组合物时,基于营养组合物成分的营养组合物。
表1:
(上表中的“,”为小数点,且由此在全世界“.”用于指示小数点的那些地区中如在USA中被解释为“.”)
在12周的时间内向年龄为6.6-17.7的患有炎症性肠病(例如局限性回肠炎)的儿童施用重构的营养制剂。
记录基线特征后,向年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童施用作为单独营养支持物的营养组合物4周,以实现临床缓解。然后继续施用8周。
在第一次访问后4周和12周随访年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童。在第一次访问和在12周时测量肌肉横截面积和骨密度。
在第一次访问时和在用代谢组学(metabonomics)方法营养干预4周后获得年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的血浆代谢特征。代谢组学方法包括根据制造商说明使用Biocrates Life Sciences AbsoluteIDQTM试剂盒。用多变量统计处理年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的血浆代谢特征,以鉴定代谢信息(生物标记)。代谢信息(生物标记)指示年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童响应于营养组合物干预的生理状态。观察到血浆代谢特征随着时间推移的代谢轨迹,这与循环氨基酸和脂质的不同差异相关。
观察到显著性差异。
观察到,用营养组合物干预4周,能够部分恢复年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的代谢特征。与年龄匹配的对照相比,在第一次访问时年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童的氨基酸和脂质的最初概括分析表明许多代谢物的显著性减少。
用营养组合物干预4周不仅能够诱导炎症性肠病急性发作影响的缓解,而且令人惊讶地恢复氨基酸苏氨酸、组氨酸和色氨酸的水平。而且,还观察到恢复氨基酸脯氨酸和谷氨酰胺的明确趋势。因此,营养组合物还可以包含氨基酸,以反映处于炎症性肠病急性发作影响的缓解状态的患者中发现的氨基酸水平的恢复。
除蛋白质分解代谢响应之外,当与年龄匹配的对照比较时,也观察到第一次访问时各个脂质种类的减少。与氨基酸响应类似,营养干预在4周后能够恢复多种脂质代谢物的合成代谢响应。结果指示营养组合物可使分解代谢响应转换为合成代谢响应。
还已发现,本公开的营养组合物在治疗的前四周内显著地减少PCDAI(儿科局限性回肠炎活动指数)–在8周内减少至最小值,如图1中描述。
此外,由于肌肉分解被认为有助于血浆氨基酸的浓度,所以如上所述恢复这些氨基酸的营养干预将减少肌肉分解代谢应激。为了表明这种效应,建立了第一次访问和在12周后肌肉横截面积的Z评分。Z评分测量了肌肉横截面积相比于参照群体的变化。如图2中所示,用营养组合物干预4周能够减轻肌肉横截面积损失并在12周内增进肌肉横截面积。
因此,表明年龄为6.6-17.7岁的患有炎症性肠病(例如局限性回肠炎)的儿童中的营养干预能够校正代谢中断,从而减轻肌肉的分解代谢响应以及减轻炎症性肠病(例如局限性回肠炎)相关的肌肉骨骼改变。
此外,注意到,维持疗法中施用营养组合物,导致显著更长地延迟复发。因此,营养组合物促进更长的缓解期,在缓解期过程中在患有炎症性肠病(例如局限性回肠炎)的患者的肌肉横截面积和骨密度得以改善。
已令人惊讶地发现,以在上述范围内的比率使用的组分的量起重要的作用,并且当在患有炎症性肠病的患者中使用组合物时是有利的。在患有炎症性肠病的患者中,营养组合物促进并改善肌肉横截面积和骨密度,营养组合物还导致显著更长地延迟复发。
鉴于已详细地描述本公开及其优点,应理解,上述的本公开的详细描述不旨在限制本文公开的范围。
本领域技术人员通过组合各个方面和实施方案能够实施本公开。本公开不限于详细描述和/或实施例。
Claims (25)
1.营养组合物,包含:
酸性酪蛋白,
维生素K1:K2的比率为3:1至1:3的维生素K,且维生素K以17.5至100μg/100g所述营养组合物的量存在,
以2.5至75μg/100g所述营养组合物的量存在的维生素D;和
n6:n3脂肪酸的比率为5:1至1:5的n6/n3脂肪酸及其混合物。
2.权利要求1的营养组合物,其中所述n6,ω-6-脂肪酸选自下组:亚麻酸C18:2、γ-亚麻酸C18:3、二十碳二烯酸C20:2、二高-γ-亚麻酸C20:3、花生四烯酸C20:4、二十二碳二烯酸C22:2、肾上腺酸C22:4、二十二碳五烯酸C22:5、二十四碳四烯酸C24:4、二十四碳五烯酸C24:5和十八碳三烯酸C18:3或其混合物。
3.权利要求1的营养组合物,其中n3,ω-3-脂肪酸选自下组:十六碳三烯酸C16:3、α-亚麻酸C18:3、十八碳四烯酸C18:4、二十碳三烯酸C20:3、二十碳四烯酸C20:4、二十碳五烯酸C20:5、二十一碳五烯酸C21:5、二十二碳五烯酸C22:5、二十二碳六烯酸C22:6、二十四碳五烯酸C24:5和二十四碳六烯酸C24:6或其混合物。
4.权利要求2的营养组合物,其中n3,ω-3-脂肪酸选自下组:十六碳三烯酸C16:3、α-亚麻酸C18:3、十八碳四烯酸C18:4、二十碳三烯酸C20:3、二十碳四烯酸C20:4、二十碳五烯酸C20:5、二十一碳五烯酸C21:5、二十二碳五烯酸C22:5、二十二碳六烯酸C22:6、二十四碳五烯酸C24:5和二十四碳六烯酸C24:6或其混合物。
5.权利要求1至4中任一项的营养组合物,还包含一种或多种氨基酸,所述氨基酸选自包含以下的组:丙氨酸、精氨酸、天冬酰胺、天冬氨酸、瓜氨酸、半胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、组氨酸、羟脯氨酸、羟基丝氨酸、羟酪氨酸、羟赖氨酸、异亮氨酸、亮氨酸、赖氨酸、蛋氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸或其组合。
6.权利要求1至4中任一项的营养组合物,还包含α-羟基异己酸、α-羟基异戊酸、α-羟基-β-甲基戊酸或其组合。
7.权利要求1至4中任一项的营养组合物,还包含一种或多种选自下组的矿物质:钠、钾、钙、磷、镁、氯化物、铁、锌、铜、锰、氟化物、铬、钼、硒、碘化物或其任何组合。
8.权利要求1至4中任一项的营养组合物,还包含一种或多种另外的维生素,所述维生素选自维生素A、维生素E、维生素C、维生素B1、维生素B2、泛酸、维生素B6、维生素B12、烟酸、叶酸、生物素和胆碱或其任何组合。
9.权利要求1至4中任一项的营养组合物,还包含一种或多种益生元,所述益生元选自包含以下的组:低聚果糖、菊粉、乳果糖、半乳低聚糖、阿拉伯树胶、大豆低聚糖、低聚木糖、低聚异麦芽糖、低聚龙胆糖、低聚乳果糖、低聚葡萄糖、果胶低聚糖、瓜尔胶、部分水解的瓜尔胶、糖醇、α葡聚糖、β葡聚糖或其组合。
10.权利要求1至4中任一项的营养组合物,还包含一种或多种益生菌,所述益生菌选自包含以下的组:酵母属(Saccharomyces)、德巴利酵母属(Debaromyces)、念珠菌属(Candida)、毕赤酵母属(Pichia)、球拟酵母属(Torulopsis)、曲霉菌属(Aspergillus)、根霉菌属(Rhizopus)、毛霉菌属(Mucor)、青霉属(Penicillium)、双歧杆菌属(Bifidobacterium)、类杆菌属(Bacteroides)、梭菌属(Clostridium)、梭杆菌属(Fusobacterium)、蜜蜂球菌属(Melissococcus)、丙酸杆菌属(Propionibacterium)、链球菌属(Streptococcus)、肠球菌属(Enterococcus)、乳球菌属(Lactococcus)、葡萄球菌属(Staphylococcus)、消化链球菌属(Peptostrepococcus)、芽孢杆菌属(Bacillus)、片球菌属(Pediococcus)、微球菌属(Micrococcus)、明串珠菌属(Leuconostoc)、魏斯氏菌属(Weissella)、气球菌属(Aerococcus)、酒球菌属(Oenococcus)、乳杆菌属(Lactobacillus)或其组合。
11.权利要求1至4中任一项的营养组合物,还包含药学上可接受的载体、风味剂和着色剂或其任何组合。
12.包含权利要求1至11中任一项的营养组合物的药物制剂。
13.包含权利要求1至11中任一项的营养组合物的管饲制剂。
14.包含权利要求1至11中任一项的营养组合物的功能食品。
15.权利要求14的功能食品,其为营养制剂或饮食补充剂。
16.包含权利要求1至11中任一项的营养组合物的饮料产品。
17.根据权利要求11的营养组合物,用于改善肌肉骨骼健康。
18.权利要求1至11任一项的营养组合物在制备用于改善患者的肌肉骨骼健康的药物中的用途,其中所述患者可任选地为儿科或青少年患者。
19.权利要求18的用途,其中所述患者患有发育延迟、发育不良、炎症性肠病、局限性回肠炎、局限性回肠炎相关的骨质减少、营养失调或其任何组合中的至少一种。
20.权利要求18至19中任一项的用途,其中所述改善的肌肉骨骼健康为改善的骨密度。
21.权利要求18至19中任一项的用途,其中所述改善的肌肉骨骼健康为改善的肌肉横截面积。
22.权利要求18至19中任一项的用途,其中所述营养组合物呈可施用形式,选自药物制剂、功能食品或其组合。
23.权利要求18至19中任一项的用途,其中所述营养组合物呈可施用形式,为管饲制剂。
24.权利要求18至19中任一项的用途,其中所述营养组合物呈可施用形式,为饮料产品。
25.权利要求22的用途,其中所述功能食品选自营养制剂或饮食补充剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12178573 | 2012-07-31 | ||
EP12178573.7 | 2012-07-31 | ||
PCT/EP2013/065948 WO2014020004A1 (en) | 2012-07-31 | 2013-07-30 | Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104582506A CN104582506A (zh) | 2015-04-29 |
CN104582506B true CN104582506B (zh) | 2016-10-19 |
Family
ID=48906252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380040258.8A Active CN104582506B (zh) | 2012-07-31 | 2013-07-30 | 用于促进患有炎症性肠病(ibd)的患者的肌肉骨骼健康的营养组合物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US9561194B2 (zh) |
EP (1) | EP2879523B1 (zh) |
JP (1) | JP6368306B2 (zh) |
CN (1) | CN104582506B (zh) |
AU (1) | AU2013298645B2 (zh) |
BR (1) | BR112015001884B1 (zh) |
CA (1) | CA2877811C (zh) |
DK (1) | DK2879523T3 (zh) |
ES (1) | ES2609654T3 (zh) |
HK (1) | HK1209984A1 (zh) |
WO (1) | WO2014020004A1 (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
EP3076991A2 (en) | 2013-09-25 | 2016-10-12 | Axcella Health Inc. | Nutritive polypeptides and formulations thereof, and methods of production and use thereof |
DK3212198T3 (en) | 2014-10-29 | 2021-03-29 | Glycom As | Synthetic composition and method for promoting mucosal healing |
ITPD20140288A1 (it) * | 2014-10-30 | 2016-04-30 | Fusaro Maria | L-integra |
WO2016069801A1 (en) * | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders |
SG10202105996WA (en) | 2014-12-23 | 2021-07-29 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
MY170519A (en) | 2014-12-23 | 2019-08-08 | 4D Pharma Res Ltd | Immune modulation |
US10768169B2 (en) | 2015-01-23 | 2020-09-08 | Societe Des Produits Nestle S.A. | Method for determining the distinctive nutritional requirements of a patient |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
DK3240554T3 (da) | 2015-06-15 | 2019-10-28 | 4D Pharma Res Ltd | Blautia stercosis og wexlerae til anvendelse til behandling af inflammatoriske og autoimmune sygdomme |
LT3360559T (lt) | 2015-06-15 | 2019-12-27 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
US20170027985A1 (en) * | 2015-07-02 | 2017-02-02 | Cambrooke Therapeutics, Inc. | Nutritional compositions |
US9839655B2 (en) | 2015-11-20 | 2017-12-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
SI3313423T1 (sl) | 2016-03-04 | 2019-07-31 | 4D Pharma Plc | Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
TW202247855A (zh) | 2016-09-13 | 2022-12-16 | 美商愛力根公司 | 非蛋白梭菌毒素組成物 |
US20180144820A1 (en) | 2016-10-24 | 2018-05-24 | Habit, Llc | System and method for implementing meal selection based on vitals, genotype and phenotype |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
LT3630136T (lt) | 2017-05-22 | 2021-06-10 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterines padermes |
JP6978514B2 (ja) | 2017-05-24 | 2021-12-08 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
SG11201912105PA (en) | 2017-06-14 | 2020-01-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MD3638271T2 (ro) | 2017-06-14 | 2021-03-31 | 4D Pharma Res Ltd | Compoziții cuprizând tulpini bacteriene |
IL292373A (en) | 2017-06-14 | 2022-06-01 | 4D Pharma Res Ltd | Preparations containing bacterial strains of the Megasphere genus and their use |
WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
JP2021503878A (ja) * | 2017-11-21 | 2021-02-15 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 筋肉の質及び/又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法 |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2020023557A1 (en) * | 2018-07-23 | 2020-01-30 | Advance International Inc. | Protein-based therapeutic nutritional products |
JP2022521345A (ja) * | 2019-02-21 | 2022-04-06 | インジェニュイティ・フーズ・インコーポレイテッド | 食品製品を栄養強化するためのコリン及びオメガ-3脂肪酸を含む組成物 |
RU2737196C1 (ru) * | 2019-06-25 | 2020-11-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный экономический университет" (УрГЭУ) | Специализированный пищевой продукт для поддержания резервных сил организма и способ его получения |
CN112790278B (zh) * | 2021-01-22 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | 一种维持骨骼健康的全价宠物罐头食品 |
CN112931876A (zh) * | 2021-03-29 | 2021-06-11 | 哈尔滨医科大学 | 一种复合营养素补充剂配方 |
WO2024158680A1 (en) | 2023-01-23 | 2024-08-02 | Best Planet Science Llc | Aqueous formulation including dissolved hydrogen gas and minerals and additives and water dispensing device producing same |
US12084335B2 (en) | 2023-01-23 | 2024-09-10 | Best Planet Science Llc | Water dispensing device |
CN116421566B (zh) * | 2023-02-16 | 2024-10-22 | 高邮市人民医院 | 一种含聚乙二醇化重组人生长激素的制剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4397926A (en) | 1981-12-03 | 1983-08-09 | Borden, Inc. | Preparation of cheese analogs from combinations of acid casein and rennet casein |
EP0527283B1 (en) * | 1991-08-12 | 1997-11-26 | Societe Des Produits Nestle S.A. | Food composition |
CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
EP0852913A1 (en) * | 1997-01-14 | 1998-07-15 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
ES2187115T3 (es) * | 1999-01-20 | 2003-05-16 | Nutricia Nv | Preparado para lactantes. |
US7759507B2 (en) | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
CN101534807A (zh) | 2006-07-14 | 2009-09-16 | 纳多制药股份公司 | 含有维生素k2的药品和类药剂营养品 |
CN101537170B (zh) | 2008-03-17 | 2012-05-30 | 哈药集团制药六厂 | 一种预防骨质疏松和骨关节病的组合物 |
US20130052274A1 (en) * | 2009-09-14 | 2013-02-28 | Nestec S.A. | Nutritional compositions including exogenous vitamin k2 |
CN102485709B (zh) | 2010-12-01 | 2014-10-22 | 天津康鸿医药科技发展有限公司 | 维生素k2类化合物的制备方法 |
-
2013
- 2013-07-30 CN CN201380040258.8A patent/CN104582506B/zh active Active
- 2013-07-30 JP JP2015524758A patent/JP6368306B2/ja active Active
- 2013-07-30 DK DK13742637.5T patent/DK2879523T3/da active
- 2013-07-30 WO PCT/EP2013/065948 patent/WO2014020004A1/en active Application Filing
- 2013-07-30 BR BR112015001884-0A patent/BR112015001884B1/pt active IP Right Grant
- 2013-07-30 EP EP13742637.5A patent/EP2879523B1/en active Active
- 2013-07-30 US US14/414,760 patent/US9561194B2/en active Active
- 2013-07-30 ES ES13742637.5T patent/ES2609654T3/es active Active
- 2013-07-30 AU AU2013298645A patent/AU2013298645B2/en active Active
- 2013-07-30 CA CA2877811A patent/CA2877811C/en active Active
-
2015
- 2015-11-11 HK HK15111129.4A patent/HK1209984A1/zh unknown
-
2016
- 2016-12-02 US US15/368,167 patent/US9763898B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2877811C (en) | 2019-07-23 |
JP2015530981A (ja) | 2015-10-29 |
EP2879523B1 (en) | 2016-11-16 |
AU2013298645A1 (en) | 2015-01-15 |
JP6368306B2 (ja) | 2018-08-01 |
WO2014020004A1 (en) | 2014-02-06 |
HK1209984A1 (zh) | 2016-04-15 |
CN104582506A (zh) | 2015-04-29 |
ES2609654T3 (es) | 2017-04-21 |
US20150174080A1 (en) | 2015-06-25 |
BR112015001884A2 (pt) | 2017-07-04 |
US20170079935A1 (en) | 2017-03-23 |
US9561194B2 (en) | 2017-02-07 |
US9763898B2 (en) | 2017-09-19 |
BR112015001884B1 (pt) | 2020-12-01 |
EP2879523A1 (en) | 2015-06-10 |
AU2013298645B2 (en) | 2016-11-03 |
DK2879523T3 (da) | 2017-01-16 |
CA2877811A1 (en) | 2014-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104582506B (zh) | 用于促进患有炎症性肠病(ibd)的患者的肌肉骨骼健康的营养组合物 | |
JP2021152062A (ja) | 過敏性腸症候群の治療のための合成組成物および方法 | |
US11123407B2 (en) | Nutritional composition for treating or preventing impaired mobility | |
CN103458710A (zh) | 具有α-HICA和瓜氨酸的营养组合物 | |
US10751362B2 (en) | Compositions and methods for managing digestive disorders and a healthy microbiome | |
CN102753043A (zh) | 优化膳食酸-碱电位的营养组合物和方法 | |
TWI639387B (zh) | 用於預防胃腸道受傷及/或促進胃腸道治癒之半乳寡糖 | |
US20230013403A1 (en) | Compositions comprising human milk oligosaccharides for use in a subject to support language development | |
JP2023071895A (ja) | 心臓弁膜症の予防又は治療に使用するための組成物 | |
TW201332555A (zh) | 在妊娠期間使用特定碳水化合物系統以降低後代後續生命中之不利健康效應 | |
BR112020010863A2 (pt) | mistura de hmos para tratamento da sensibilidade ao trigo | |
EP4255222A1 (en) | Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration | |
EP3091975A1 (en) | Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring | |
WO2014150687A1 (en) | Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring | |
ES2870568T3 (es) | Productos nutricionales para fomentar una deglución segura para individuos con disfagia | |
EP3184111A1 (en) | Compositions comprising carbohydrates | |
EP2745706A1 (en) | Methods for maintaining bone quality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: Vevey Patentee after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Patentee before: Nestle Products Technical Assistance Co., Ltd. |